Comprehensive, up-to-date information on HIV/AIDS treatment, prevention, and policy from the University of California San Francisco

a. 25-34

b. 35-44

c. 45-54

d. > 55

a. It has a long half-life

b. It is FDA approved for PrEP

c. It is well tolerated

d. It achieves high concentrations in the rectum

e. All of the above

a. Renal failure

b. Increased number of unprotected anal sex acts

c. Nausea in the first 4 weeks after starting study drug

d. Fractures

e. Missed pills

a. Truvada doesn't work as well in women as it does in men

b. Adherence was too low

c. The women in the study were not at high risk for HIV

d. The women in the study used condoms, and therefore didn't need PrEP

a. Very adherent to study drug

b. Moderately adherent to study drug

c. Acutely infected with HIV at the time they started study drug

d. There were no participants in the PrEP studies who acquired ART resistance